erenumab (aimovig) is the first of four new migraine drugs in the pipeline that target calcitonin gene-related peptide (cgrp), a molecule that's produced in nerve cells of the
.
a genetic disorder that leads to underdeveloped sweat glands and teeth was treated in the womb
.
schneider said that he is "not aware of any relevant risk of the drug" and that his team has "not observed side effects in thousands of treated animals."
.
logout
.
. sign in to get notified via email when new comments are made.
.